Patents Examined by Melissa Schmidt
  • Antisense modulation of Ship-2 expression
    Patent number: 6025198
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Ship-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ship-2. Methods of using these compounds for modulation of Ship-2 expression and for treatment of diseases associated with expression of Ship-2 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: February 15, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Antisense modulation of PTEN expression
    Patent number: 6020199
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PTEN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTEN. Methods of using these compounds for modulation of PTEN expression and for treatment of diseases associated with expression of PTEN are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: February 1, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of Sentrin expression
    Patent number: 5985664
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Sentrin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Sentrin. Methods of using these compounds for modulation of Sentrin expression and for treatment of diseases associated with expression of Sentrin are provided.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: November 16, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brenda F. Baker, Lex M. Cowsert
  • Antisense inhibition of interleukin-15 expression
    Patent number: 5985663
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Interleukin-15. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin-15. Methods of using these compounds for modulation of Interleukin-15 expression and for treatment of diseases associated with expression of Interleukin-15 are provided.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: November 16, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Antisense modulation of cellular inhibitor of Apoptosis-2 expression
    Patent number: 5958771
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Cellular Inhibitor of Apoptosis-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Cellular Inhibitor of Apoptosis-2. Methods of using these compounds for modulation of Cellular Inhibitor of Apoptosis-2 expression and for treatment of diseases associated with expression of Cellular Inhibitor of Apoptosis-2 are provided.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: September 28, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Elizabeth J. Ackermann, Lex M. Cowsert
  • Antisense modulation of AKT-1 expression
    Patent number: 5958773
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Akt-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Akt-1. Methods of using these compounds for modulation of Akt-1 expression and for treatment of diseases associated with expression of Akt-1 are provided.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: September 28, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of G-alpha-11 expression
    Patent number: 5951455
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-11. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-11. Methods of using these compounds for modulation of G-alpha-1l expression and for treatment of diseases associated with expression of G-alpha-11 are provided.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: September 14, 1999
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Lex M. Cowsert